医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kraig Biocraft Laboratories Completes Construction of Spider Silk Biotech Research Laboratory in Vietnam

2019年08月08日 PM08:05
このエントリーをはてなブックマークに追加


 

ANN ARBOR, Mich.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has completed construction of its new biotech research laboratory in Vietnam. The new laboratory suite is located within the Company’s recombinant spider silk production facility in Quang Nam, Vietnam and consists of eleven separate labs. These new labs are a key piece of the Company’s spider silk commercialization program and were part of the, now complete, renovation efforts at the Prodigy Textiles factory, the Company’s wholly owned subsidiary and production arm.

This new laboratory suite was built to support production ramp up and will serve as a testing and quality control facility for the commercialization of the Company’s recombinant spider silk technologies. To ensure compliance with regulations, related to genetically modified technologies, this laboratory was built to the design and specification of the Vietnamese Ministry of Science and Technology (MoST). Moving into the future, the Company anticipates utilizing these new laboratories for the development of future innovations in spider silk fibers and products to complement the Company’s existing technologies, which are now moving to commercialization.

“With these new laboratories and the completion of the Prodigy Textiles factory renovations, we are now ready to start the transition and expansion of our recombinant spider silk production into the new factory,” said COO Jon Rice. “We purposefully designed our laboratories to mirror those of the MoST, where the initial evaluation and approval of our specialized silkworms were finalized, in order to accelerate our commercial ramp up.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005214/en/

CONTACT

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease